Yemen faces the world's most severe manufactured humanitarian catastrophe in 2026, driven by economic collapse, climate ...
In the Tampa Bay region, almost one in five low-income residents under 65 does not have health insurance. The stark finding ...
Background Alcohol use disorder and treatment-resistant depression (TRD) often co-occur, presenting a major clinical challenge with limited effective treatments. However, ketamine produces rapid ...
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...
The movement-related benefits of Itvisma were maintained or continued to deepen over about 15 months after treatment, trial ...
Sobi® (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study (NCT06694701), evaluating Gamifant® (emapalumab) in patients with interferon-gamma (IFNγ)-driven sepsis (IDS), ...
Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Paris, March 18, 2026. The US Food and Drug Administration (FDA) has granted Breakthrough Therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results